Jul 2026· Cancer Research· Vol 86, pp. A023-A023· 0 citations
TL;DR
Investigation of OGM’s efficacy in inducing ferroptosis in DIPG cells suggested that GPR68 inhibition is an attractive therapeutic target for DIPG, and GPR68 inhibition mirrors the effects observed in GBM, inducing ATF4-dependent ferroptotic cell death.
Abstract
Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive pediatric brainstem tumor with limited treatment options and dismal prognosis. Previously, we showed that Ogremorphin (OGM), a specific GPR68 inhibitor, induced ferroptosis in glioblastoma multiforme (GBM) cells. Given their shared originating cell type, we investigated OGM’s efficacy in inducing ferroptosis in DIPG cells, using normal human astrocytes (NHAs) for comparison.
DIPG cell lines (SF7761, DIPG36, DIPG007) and NHAs were evaluated. OGM sensitivity was assessed via CellTiter-Glo viability assays. Ferroptosis markers including glutathione (GSH) levels, lipid peroxidation (BODIPY C11), and qRT-PCR of ATF4 and SLC7A11 were measured. Rescue experiments used liproxstatin-1 for ferroptosis and Z-VAD-FMK for apoptosis. Genetic validation used shRNA knockdown and overexpression of GPR68/ATF4, plus an ATF4 luciferase reporter assay.
OGM treatment in N5 media revealed that NHAs were more resistant (LD50 = 3.84 µM) than DIPG cells (LD50 ≤ 0.79 µM). DIPG sensitivity to OGM was comparable to GBM. Knockdown of GPR68 via shRNA confirmed that GPR68 inhibition induces cell death in DIPG cells. OGM robustly triggered ferroptosis marked by elevated lipid radicals, reduced GSH, and increased ATF4 and SLC7A11 expression in DIPG and NHA cells, except SF7761, which lacked SLC7A11 induction. Furthermore, liproxstatin-1 rescued the loss of cell viability, whereas Z-VAD-FMK had no effect. ATF4 overexpression caused cell death, while its knockdown rescued OGM-mediated effects.
These findings suggest that GPR68 inhibition is an attractive therapeutic target for DIPG. Notably, GPR68 inhibition mirrors the effects observed in GBM, inducing ATF4-dependent ferroptotic cell death.
Leif R. Neitzel, Charles C. Hong. Inhibition of GPR68 induces ferroptosis in diffuse intrinsic pontine gliomas [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight against Rare Cancers; 2026 Jul 18-20; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(14_Suppl):Abstract nr A023.
GPX4 is identified as the principal mediator of MLN4924-induced ferroptosis and dual targeting of GPX4 transcription and activity represents a promising therapeutic strategy for GBM, establishing that dual targeting of GPX4 transcription and activity represents a promising therapeutic strategy.
Zhou Jing, Fangyuan Wang, Hao Li et al.· Carcinogenesis· 0 citations
The GPX-4/GCLM axis, which balances redox, is highly expressed and crucial for GBM cell survival and aggressive biological behavior and may be a valuable adjunct to diagnosis, as demonstrated by RSL3, FIN56, and BSO.
M. Behera, S. Purkait, Amit Ghosh et al.· Neuro-Oncology· 0 citations
Preliminary evidence suggests that ONC212 induces ferroptosis-associated cell death through modulation of oxidative stress and ferroptosis‑associated gene expression is provided, and Targeting ferroptosis with ONC212 may represent a promising therapeutic strategy for GBM.
E. Karabacak, C. Hacıoğlu· Düzce Tıp Fakültesi Dergisi· 0 citations
A link between a more immunologically active TME and response to ONC201 in patients with DMG is identified, and that changes in NFkB signaling occurred following imipridone treatment of the THP1 cell line.
Tyler Roady, Connor Purcell, Jillian Strandberg et al.· Journal of Immunology· 0 citations
Findings suggest that Mumio exerts anticancer effects through oxidative stress-mediated apoptosis and modulation of ferroptosis pathways, suggesting its potential use alongside standard therapy.
B. Dalbayrak, Zeynep Demirel, Ayşe Şevval Martin et al.· Current pharmaceutical desig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.